{"id":45565,"date":"2022-06-28T08:01:33","date_gmt":"2022-06-28T06:01:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/"},"modified":"2022-06-28T08:01:33","modified_gmt":"2022-06-28T06:01:33","slug":"transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/","title":{"rendered":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae"},"content":{"rendered":"
\n

STRASBOURG, France & LUND, Sweden–(BUSINESS WIRE)–#HBV<\/a>–Regulatory News:\n<\/p>\n

<\/a><\/p>\n

\nTransgene (Euronext Paris: TNG)<\/b>, a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (\u201cBioInvent\u201d) (Nasdaq Stockholm: BINV),<\/b> a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ., USA, to evaluate the oncolytic virus BT-001 in combination with MSD\u2019s anti-PD-1 therapy KEYTRUDA\u00ae (pembrolizumab) in a Phase I\/IIa clinical trial for the treatment of patients with solid tumors.<\/b>\n<\/p>\n

\nUnder the terms of the supply agreement, MSD will provide pembrolizumab to be used in combination with BT-001 in the ongoing Phase I\/IIa clinical trial.\n<\/p>\n

\n\u201cBy combining BT-001 with the anti-PD-1 drug KEYTRUDA\u00ae we expect to optimize the patient\u2019s immune response to induce a strong and effective anti-tumor response. This agreement will allow us to move further on the clinical development of our promising co-developed oncolytic candidate BT-001<\/i>\u201d said Hedi Ben Brahim, CEO of Transgene.<\/b>\n<\/p>\n

\n\u201cWe are very pleased to be signing another collaboration with MSD, supporting the expansion of the clinical trial program of BT-001, the oncolytic virus expressing our proprietary anti-CTLA-4 antibody, jointly developed by Transgene and BioInvent. It marks a further validation of our expanding and promising clinical pipeline of anti-cancer treatments, which currently encompasses three compounds in four ongoing clinical trials<\/i>\u201d added Martin Welschof, CEO of BioInvent<\/b>.\n<\/p>\n

\nRecruitment in the clinical study (NCT04725331<\/a>) is ongoing. The trial is a Phase I\/IIa of BT-001, which is being co-developed as part of a 50\/50 collaboration between Transgene and BioInvent, as a single agent and in combination with KEYTRUDA\u00ae for the treatment of solid tumors.\n<\/p>\n

\nKEYTRUDA\u00ae is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.\n<\/p>\n

\n***\n<\/p>\n

\nAbout the trial<\/i><\/b>\n<\/p>\n

\nThe ongoing Phase I\/IIa (NCT04725331) study is a multicenter, open label, dose-escalation trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). Patient inclusions are ongoing in Europe (France, Belgium) and the trial has been authorized in the US.\n<\/p>\n

\nThis Phase I is divided into two parts. In part A, patients with metastatic\/advanced tumors receive single agent, intra-tumoral administrations of BT-001. Part B will explore the combination of intra-tumoral injections of BT-001 with pembrolizumab. The Phase IIa will evaluate the combination regimen in several patient cohorts with different tumor types. These expansion cohorts will offer the possibility of exploring the activity of this approach to treat other malignancies not traditionally addressed with this type of treatment.\n<\/p>\n

\nAbout BT-001<\/i><\/b>\n<\/p>\n

\nBT-001 is an oncolytic virus generated using Transgene\u2019s Invir.IO\u2122 platform and its patented large-capacity VVcop<\/sub>TK–<\/sup>RR–<\/sup> oncolytic virus, which has been engineered to encode both a Treg-depleting human recombinant anti-CTLA-4 antibody generated by BioInvent\u2019s proprietary n-CoDeR\u00ae<\/sup>\/F.I.R.S.T\u2122 platforms, and the human GM-CSF cytokine. By selectively targeting the tumor microenvironment, BT-001 is expected to elicit a much stronger and more effective antitumoral response. As a consequence, by reducing systemic exposure, the safety and tolerability profile of the anti-CTLA-4 antibody will be greatly improved.\n<\/p>\n

\nBT-001 is being co-developed as part of a 50\/50 collaboration on oncolytic viruses between Transgene and BioInvent. To know more on BT-001, watch our video here<\/a>.\n<\/p>\n

\nAbout Transgene<\/i><\/b>\n<\/p>\n

\nTransgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene\u2019s programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.\n<\/p>\n

\nThe Company\u2019s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac<\/i>\u00ae platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO\u2122 platform).\n<\/p>\n

\nWith Transgene\u2019s myvac<\/i>\u00ae platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The myvac<\/i>\u00ae approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.\n<\/p>\n

\nWith its proprietary platform Invir.IO\u2122, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses. Transgene has an ongoing Invir.IO\u2122 collaboration with AstraZeneca.\n<\/p>\n

\nAdditional information about Transgene is available at: www.transgene.fr<\/a>.\n<\/p>\n

\nFollow us on Twitter: @TransgeneSA<\/a>\n<\/p>\n

\nAbout BioInvent<\/i><\/b>\n<\/p>\n

\nBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase l\/ll trials for the treatment of hematological cancer and solid tumors, respectively. The Company\u2019s validated, proprietary F.I.R.S.T\u2122 technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company\u2019s own clinical development pipeline or for additional licensing and partnering.\n<\/p>\n

\nThe Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company\u2019s fully integrated manufacturing unit. More information is available at www.bioinvent.com<\/a>.\n<\/p>\n

\nFollow us on Twitter: @BioInvent<\/a>\n<\/p>\n

\nTransgene disclaimer<\/i><\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company\u2019s activities, perspectives, financial situation, results, regulatory authorities\u2019 agreement with development phases, and development. The Company\u2019s ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and\/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company\u2019s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (\u201cFacteurs de Risque\u201d) section of the Universal Registration Document, available on the AMF website (http:\/\/www.amf-france.org<\/a>) or on Transgene\u2019s website (www.transgene.fr<\/a>). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.<\/i>\n<\/p>\n

\nBioInvent disclaimer<\/i><\/b>\n<\/p>\n

\nThe press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.<\/i>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nTransgene:<\/b>
Lucie Larguier<\/b>
Director Corporate Communications & IR
\n
+33 (0)3 88 27 91 04
\n
investorrelations@transgene.fr<\/a>\n<\/p>\n

\nMedia Transgene:<\/b>
MEDiSTRAVA Consulting<\/b>
David Dible\/Sylvie Berrebi<\/b>
+44 (0)203 928 6900
\n
transgene@medistrava.com<\/a>\n<\/p>\n

\nBioInvent:<\/b>
Cecilia Hofvander
\n
Senior Director Investor Relations
\n
+46 (0)46 286 85 50
\n
cecilia.hofvander@bioinvent.com<\/a>\n<\/p>\n

\nBioInvent International AB (publ):<\/b>
Co. Reg. No. Org nr: 556537-7263
\n
Visiting address: Ideongatan 1
\n
Mailing address: 223 70 LUND
\n
Phone: +46 (0)46 286 85 50
\n
www.bioinvent.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

STRASBOURG, France & LUND, Sweden–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (\u201cBioInvent\u201d) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45565","6":"format-standard","7":"category-industry"},"yoast_head":"\nTransgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"STRASBOURG, France & LUND, Sweden–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (\u201cBioInvent\u201d) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-28T06:01:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220627005554\/en\/1192643\/21\/Logo_Transgene.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae\",\"datePublished\":\"2022-06-28T06:01:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/\"},\"wordCount\":1231,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005554\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/\",\"name\":\"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005554\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"datePublished\":\"2022-06-28T06:01:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005554\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220627005554\\\/en\\\/1192643\\\/21\\\/Logo_Transgene.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/","og_locale":"en_US","og_type":"article","og_title":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae - Pharma Trend","og_description":"STRASBOURG, France & LUND, Sweden–(BUSINESS WIRE)–#HBV–Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (\u201cBioInvent\u201d) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immuno-modulatory antibodies for cancer immunotherapy, today announced a clinical trial collaboration and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-28T06:01:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220627005554\/en\/1192643\/21\/Logo_Transgene.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae","datePublished":"2022-06-28T06:01:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/"},"wordCount":1231,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220627005554\/en\/1192643\/21\/Logo_Transgene.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/","url":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/","name":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220627005554\/en\/1192643\/21\/Logo_Transgene.jpg","datePublished":"2022-06-28T06:01:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220627005554\/en\/1192643\/21\/Logo_Transgene.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220627005554\/en\/1192643\/21\/Logo_Transgene.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/transgene-and-bioinvent-announce-clinical-trial-collaboration-and-supply-agreement-with-msd-to-evaluate-bt-001-in-combination-with-keytruda\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Transgene and BioInvent Announce Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BT-001 in Combination with KEYTRUDA\u00ae"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45565","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45565"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45565\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45565"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45565"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45565"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}